IMMUNIC Seeks Shareholder Approval for Reverse Stock Split to Maintain Nasdaq Listing and Fulfill $200M Financing Obligation

summarizeSummary

Immunic, Inc. is seeking shareholder approval for a reverse stock split (1-for-10 to 1-for-30) to meet Nasdaq's minimum bid price requirement and satisfy a key condition of its recent $200 million private placement.

check_boxKey Events

• Shareholder Vote on Reverse Stock Split

  The company is calling a special meeting for stockholders to vote on authorizing the Board of Directors to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30.

• Nasdaq Listing Compliance

  The reverse stock split is intended to increase the per-share trading price to regain compliance with Nasdaq's $1.00 minimum bid price requirement by the June 22, 2026 deadline, following its transfer to the Nasdaq Capital Market.

• Condition of Recent $200M Financing

  Approval of the reverse stock split is a mandatory obligation under the securities purchase agreement for the $200 million private placement that closed on February 17, 2026. Failure to obtain approval would result in a breach of this critical financing agreement.

auto_awesomeAnalysis

Immunic, Inc. is seeking shareholder approval for a reverse stock split, a critical step to address its non-compliance with Nasdaq's minimum bid price requirement. The company previously transferred its listing to the Nasdaq Capital Market (as disclosed in the 8-K on 2026-01-06) and faces a June 22, 2026 deadline to regain compliance. More importantly, this proxy statement reveals that obtaining shareholder approval for the reverse stock split is a mandatory obligation under the recent $200 million private placement agreement (announced in the 8-K on 2026-02-13). Failure to secure this approval would put the company in breach of the financing terms, which would have severe adverse effects on its business and operations. While a reverse stock split is generally viewed negatively as it often signals underlying issues, in this case, it is a necessary defensive measure to ensure continued listing and, crucially, to uphold a significant capital raise that is vital for the company's runway.